What Cellevate does

Cellevate AB is a Swedish biotech company founded in 2014 as a spin-out from NanoLund at Lund University, headquartered at Medicon Village in Lund, Sweden. The company develops and commercializes next-generation cell culture products for upstream bioprocessing, built on its proprietary Cellevat3d® nanofiber technology platform. The core technology uses post-electrospinning fabrication to produce cellulose-based monofibers and 3D cross-linked fiber structures that provide up to 60 times larger surface area than conventional bead-based microcarriers, enabling high cell-density 3D spheroid cultures in standard stirred-tank bioreactors.

The commercial product portfolio comprises two launched products: Cellevat3d® nanofiber microcarriers for viral vector production (AAV, lentivirus) — launched globally at BIO-Europe 2024 — and Cellevat3d® VAX nanofiber microcarriers specifically optimized for Vero cell-based viral vaccine production, launched at the World Vaccine Congress Europe in October 2025. Two pipeline products extend the platform: iPSC nanofiber microcarriers (expected 2027 launch, supported by a EUR 1M Eurostar grant consortium with Fraunhofer IBMT and OLS) and nanofiber macrocarriers for MSC and cell therapy applications in packed- and fixed-bed bioreactors. Validated performance includes 3-13.5-fold higher viral titers, up to 85% production cost reductions, and 70% cost reductions per gene therapy dose across multiple independent studies.

Cellevate sells directly to biopharmaceutical companies, CDMOs, and academic research institutions via an enterprise field-sales motion, with a dedicated US sales and support team established in 2024-2025. Products are manufactured at the company's ISO 9001:2015-certified, GMP-compliant cleanroom facility in Lund, with quote-based bulk pricing (€1,500 for a 0.2g starter pack, commercial volumes quoted). The company is venture capital-backed (Industrifonden, EIC Fund, Onsight Ventures, Almi Invest) with approximately €6.6M in total equity funding plus €3.48M in non-dilutive grants as of early 2026. The leadership team and board include senior bioprocessing veterans from Cytiva, Sartorius, Lonza, AstraZeneca, and GE Healthcare.

Name

Cellevate

Legal name

Cellevate AB

Website

https://cellevate.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Cellevate AB is a Swedish biotech company developing and commercializing proprietary cellulose-based nanofiber microcarriers (Cellevat3d®) for upstream bioprocessing, sold directly to biopharmaceutical companies and CDMOs for viral vector, viral vaccine, and cell therapy manufacturing.

Ownership category

akta.pro rank

Product category

Bioprocessing Consumables

NAICS

Research and Development in Nanotechnology (541713), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) (2820)

akta.pro primary industry

Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)

akta.pro secondary industries

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Nanofiber microcarriers
• Viral vector production
• Cell culture systems
• Upstream bioprocessing
• Biopharmaceutical consumables

Headquarters

HQ city

Lund

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Nanofiber Microcarrier Products: Sale of Cellevat3d® nanofiber microcarriers for viral vector, viral vaccine, and cell therapy biomanufacturing. Products available for ordering include Starter Pack (€1500 for 0.2g) and bulk quantities (500g). Revenue generated through direct product sales to biopharmaceutical companies and CDMOs.
2. Pipeline Products: Future revenue expected from iPSC nanofiber microcarriers (launch 2027) and nanofiber macrocarriers for cell therapy applications.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Cellevate develops and sells cellulose-based nanofiber microcarriers under the Cellevat3d® brand for upstream bioprocessing of viral vectors (AAV, lentivirus) and viral vaccines. Products are manufactured at a GMP-compliant cleanroom in Lund and sold in starter packs (0.2 g) and bulk (500 g) quantities directly to biopharmaceutical companies and CDMOs. The platform addresses yield, cost, and scalability challenges in cell and gene therapy and vaccine manufacturing.

Product overview

Cellevate offers a platform-based product portfolio centered on its proprietary Cellevat3d® nanofiber technology for upstream bioprocessing. The platform consists of two commercialized products: Cellevat3d® nanofiber microcarriers (for viral vector production including AAV and lentivirus) and Cellevat3d® VAX nanofiber microcarriers (for viral vaccine production). Two pipeline products extend the platform: iPSC nanofiber microcarriers (expected 2027 launch for stem cell therapy applications) and nanofiber macrocarriers (for cell therapy using mesenchymal stem cells). All products are based on cellulose-derived nanofibers that provide up to 60x larger surface area compared to conventional bead-based microcarriers, enabling 3D spheroid formation, higher cell densities, and significantly improved viral titers. Products are scalable from R&D to commercial production in stirred tank bioreactors and are designed for single-use bioprocessing workflows.

Differentiator

Problem solved

Functional benefit

Brands

• Cellevat3d: Proprietary nanofiber technology platform for cell culture products enabling industrial-scale production of nanofiber-based cell culture systems for biomanufacturing.
• Cellevat3d VAX
• Cellevat3d iPSC
• Cellevat3d nanofiber macrocarriers

Products and services

• Cellevat3d® nanofiber microcarriers Starter Pack A novel category of nanofiber-based cell culture microcarriers for viral vector production (AAV, lentivirus) in stirred-tank bioreactors. Cellulose-based nanofibers with average 500 nm diameter, 75 µm length, and cationic surface charge provide up to 60x larger surface area (53,000 cm²/g) than bead-based microcarriers, enabling homogeneous 3D spheroid formation, high cell viability (94–99%), and 3–5-fold higher viral vector titers. Sold to biopharmaceutical developers and CDMOs for gene therapy manufacturing.
• Cellevat3d® VAX nanofiber microcarriers Nanofiber microcarriers specifically optimized for viral vaccine production using adherent cell lines such as Vero cells in stirred-tank bioreactors. Promotes homogeneous 3D spheroid cultures with >13-fold higher viral vaccine titers versus industry-standard microcarriers and >90% transfection efficiency. Animal-component-free and manufactured under GMP-compliant, ISO 9001:2015 certified, 21 CFR 820 quality system. Targeted at vaccine manufacturers including emerging applications such as oncolytic cancer vaccines.
• Cellevat3d® iPSC nanofiber microcarriers Pipeline nanofiber microcarriers designed for large-scale production of induced pluripotent stem cells (iPSCs) for regenerative medicine and cell therapy applications. Built on the same post-electrospinning cellulose nanofiber platform used in commercial products, scaled for iPSC expansion. Currently in development with expected commercial launch in 2027.
• Cellevat3d® nanofiber macrocarriers Pipeline product consisting of cross-linked nanofiber-based cellulose macrocarriers designed for cell therapy applications in packed- and fixed-bed bioreactors. Specifically targeted at human mesenchymal stem cell (hMSC) production and other adherent cell therapy manufacturing processes. Demonstrated 19-fold increase in cell density with retained high cell viability in development studies.

Quantifiable outcome

• 13.5-fold higher infectious EV71 vaccine titers (1.60×10⁶ TCID50/mL vs 1.19×10⁵ TCID50/mL)
• +9 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

15 partnerships are on record, tiered important, core, major and supporting.

• InVitria, Inc.importantStrategic or Co-development Partner · 10 March 2026Strategic collaboration agreement integrating InVitria's high-performance, chemically defined, animal-component-free cell culture media with Cellevate's Cellevat3d® nanofiber microcarrier platform. Joint development program includes microcarrier screening, process optimization, virus production studies, and scale-up activities aimed at generating performance data to support future commercial deployment in viral vaccine manufacturing.
• IntravacccoreTechnology or Integration · 19 August 2025CDMO conducted benchmarking study demonstrating 11.4-fold higher infectious enterovirus titers and 17-fold increase in cell-specific virus yield using Cellevat3d® nanofiber microcarriers vs industry-standard microcarriers.
• Fraunhofer IBMTmajorStrategic or Co-development Partner · 25 April 2025Eurostar consortium partner providing expertise in applied stem cell research and biomedical engineering. Three-year project validating Cellevat3d® nanofiber microcarriers for large-scale iPSC production in OLS bioreactor, including benchmarking data vs market standard processes.
• OLS (Omni Life Science)majorStrategic or Co-development Partner · 25 April 2025German bioreactor company and Eurostar consortium partner providing specialized knowhow in cutting-edge bioreactor technologies and cell culture systems for large-scale iPSC production validation.
• UCL (University College London)coreTechnology or Integration · 25 October 2024Academic collaborator conducting AAV9 benchmarking studies demonstrating 3.1-fold significant increase in vector titer. Dr. John Counsell (Associate Professor in Medical Innovation) presenting validation results.
• Max Planck Society (Max Planck Institute for Dynamics of Complex Technical Systems)importantStrategic or Co-development Partner · 20 June 2023Collaboration for research in viral vaccine production with Dr. Yvonne Genzel's upstream processing team at Max Planck Institute in Magdeburg, Germany.
• Dr. Yvonne Genzel (Max Planck Institute)importantTechnology or Integration · 29 May 2023Scientific Advisory Board member, globally recognized expert in vaccine bioprocess engineering, particularly animal cell culture and virus production in bioreactor systems. Contributed to vaccine production validation program.
• Dr. Thierry ZieglerimportantTechnology or Integration · 4 May 2023Scientific Advisory Board member with 25+ years expertise in biopharmaceutical development and production (Merck-Serono, Igyxos, Sanofi, Cellectis). Provides expertise in CAR-T, CMC, and regulatory aspects of biologics.
• RISE Research Institutes of SwedenimportantTechnology or Integration · 26 April 2023Vinnova-funded collaborative study demonstrating positive feasibility results for AAV vector transfection and production using Cellevat3d™ microcarriers.
• University of DundeecoreTechnology or Integration · 29 March 2023Expanded collaboration for cell culture experiments optimizing use of Cellevat3d™ microcarriers in AAV-based production for cell and gene therapy. Dr. Jean-Christophe Bourdon's team conducting validation studies since 2021, generating benchmarking data for commercial launch.
• AdBIOPRO ConsortiumimportantStrategic or Co-development Partner · 22 March 2023Competence Centre for Advanced BioProduction at KTH with 24 member organizations including AstraZeneca, Cytiva, BioInvent, and others. Cellevate is technology provider for upstream AAV, lentivirus, and cell therapy bioproduction.
• Testa CenterimportantTechnology or Integration · 20 December 2022Vinnova/STUNS Life Science funded validation study at Testa Center in Uppsala, Sweden, demonstrating successful scale-up of Cellevat3d® nanofiber microcarriers in 10L Xcellerex XDR single-use stirred tank bioreactor.
• Dr. Véronique Chotteau (KTH)importantTechnology or Integration · 22 November 2022Scientific Advisory Board member and Principal Investigator of Cell Technology group at KTH. Director of AdBIOPRO consortium, world-leading expert in mammalian cell culture and continuous bioprocessing.
• SmiLe IncubatorsupportingOthers · 9 November 2022SmiLe alumni member using their newly upgraded laboratories equipped for gene therapy applications at Medicon Village in Lund.
• Karolinska Institutet and Karolinska University HospitalimportantTechnology or Integration · 1 February 2022Vinnova-funded collaboration (5.25 MSEK grant) for development of more effective production of extracellular vesicles from hematopoietic and mesenchymal stem cells using Cellevat3d® nanofiber technology.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Cytiva: Global bioprocessing leader (formerly GE Healthcare Life Sciences) selling Cytodex microcarriers, bioreactors and upstream consumables. Direct competitor in microcarriers for viral vector and vaccine production, and broader portfolio incumbent across cell and gene therapy bioprocessing.
• Sartorius: Major bioprocessing supplier with CultiSpher-S and other microcarriers plus single-use bioreactors. Competes head-to-head with Cellevat3d® in upstream microcarriers for cell and gene therapy applications.
• Thermo Fisher Scientific: Diversified life sciences giant offering microcarriers (e.g., Gibco) and complete upstream bioprocessing workflows. A broad incumbent in the same customer workflows as Cellevate for viral vector and vaccine manufacturing.
• Corning Life Sciences: Supplies Corning® microcarriers and cell culture vessels widely used in bioprocessing. Competes with Cellevate in adherent cell culture substrates for vaccine and cell therapy production.
• Eppendorf: Manufacturer of bioreactors and bioprocessing equipment serving similar upstream cell culture customers. Adjacent competitor in the upstream bioprocessing ecosystem where Cellevate's microcarriers are deployed.

Direct peers

• PBS Biotech: Specialist in single-use bioreactors and cell culture systems for cell and gene therapy manufacturing. Direct peer in the upstream bioprocessing tooling stack where Cellevate's nanofiber microcarriers are used.
• FUJIFILM Irvine Scientific: Supplies cell culture media and bioprocessing solutions for cell and gene therapy, regenerative medicine and vaccine manufacturing. Comparable as a supplier of upstream cell culture inputs alongside Cellevate's microcarriers.

Emerging players

• RoosterBio: Emerging supplier of MSC and cell therapy enabling products (media, cells, bioprocess media). Relevant comparable in the cell therapy upstream workflow that Cellevate's macrocarriers pipeline targets.
• Stemcell Technologies: Supplies cell culture media, substrates and reagents for stem cell and cell therapy workflows. Comparable emerging player in iPSC and stem cell culture consumables, adjacent to Cellevate's iPSC microcarrier pipeline.
• CelVivo: Develops 3D cell culture technologies including hydrogels and scaffolds for cell expansion. Comparable emerging player in 3D and scaffold-based cell culture substrates for advanced cell therapy applications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/CellevateAB
• LinkedInlinkedin.com/company/4790677

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellevate